Israeli Drug Trial Shows Promise for Celiac Disease Patients
Translated & summarized from i24NEWS by baba
Israeli drugmaker Teva reported positive Phase 2 trial results for an experimental antibody, TEV '408, which significantly reduced gluten-induced intestinal damage and improved symptoms in celiac disease patients. The antibody was well-tolerated and offers potential for a new treatment beyond strict gluten-free diets.
The story in 5 lines · by baba
- Teva's experimental antibody TEV '408 shows positive results in celiac disease trial.
- The drug significantly reduced gluten-induced intestinal damage.
- It also improved digestive symptoms and reduced inflammation.
- The antibody was well-tolerated with no safety concerns.
- This offers potential new treatment beyond gluten-free diets.
Israeli pharmaceutical company Teva announced significant positive results from a clinical trial of an experimental antibody for adults with celiac disease. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful prevention of intestinal damage caused by gluten exposure compared to a placebo, after eight weeks of treatment.
The study involved 50 adults with celiac disease. The experimental antibody, TEV '408, not only prevented gluten-induced intestinal damage but also showed a positive effect in reducing intestinal inflammation and improving digestive symptoms when compared to a placebo. The antibody was found to be well-tolerated, with no safety concerns identified to date.
Dr. Eric Hughes, Teva's Senior Vice President and Head of Global R&D and Chief Medical Officer, stated that gluten-free diets, while the only option for celiac patients, often still leave individuals suffering from symptoms, intestinal damage, and a significant impact on their daily lives. He highlighted that these trial results underscore the potential to move beyond managing gluten exposure and to treat the disease at its biological source.
Hughes added that the findings strengthen Teva's confidence in focusing on the IL-15 pathway as an approach to reduce immune-mediated intestinal damage. The company is advancing the development of this potential new treatment for celiac disease.
Mentioned
